Table 2.

T 50% values and max % degradation of BRD4 after MZ1 or dBET1 treatment

Cell line	MZ1 t 50%, min	MZ1 Max %, POC	dBET1 t 50%, min	dBET1 max %, POC
A375	42 ± 1, n = 2	2 ± 1, n = 2	60 ± 1, n = 2	6 ± 0, n = 2
NCIH23	22 ± 2, n = 2	1 ± 0, n = 2	>720, n = 2	54 ± 3, n = 2
NCIH460	49 ± 5, n = 2	4 ± 1, n = 2	>720, n = 2	77 ± 4, n = 2
HCC15	15 ± 1, n = 2	1 ± 0, n = 2	>720, n = 2	63 ± 4, n = 2
A427	27 ± 0, n = 2	0 ± 0, n = 2	389 ± 26, n = 2	48 ± 3, n = 2
A549	40 ± 13, n = 2	4 ± 1, n = 2	161 ± 11, n = 2	35 ± 1, n = 2
NCIH1299	23 ± 1, n = 2	2 ± 1, n = 2	85 ± 10, n = 2	20 ± 2, n = 2
NCIH1568	42 ± 2, n = 2	3 ± 0, n = 2	137 ± 46, n = 2	22 ± 2, n = 2
NCIH358	21 ± 1, n = 2	1 ± 1, n = 2	95 ± 35, n = 2	24 ± 5, n = 2
NCIH441	35 ± 2, n = 2	3 ± 1, n = 2	64 ± 12, n = 2	9 ± 2, n = 2
NCIH661	14 ± 2, n = 2	0 ± 0, n = 2	50 ± 10, n = 2	8 ± 2, n = 2
NCIH838	31 ± 2, n = 2	2 ± 1, n = 2	57 ± 9, n = 2	8 ± 2, n = 2

DC50 values shown were calculated from 10-point dose-response curves are shown with T50% and max % degradation for dBET1 and MZ1 time course treatment of each cell line.